See more : Nittoc Construction Co., Ltd. (1929.T) Income Statement Analysis – Financial Results
Complete financial analysis of ThermoGenesis Holdings, Inc. (THMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ThermoGenesis Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Jyske Bank A/S (JYSKY) Income Statement Analysis – Financial Results
- EIH Limited (EIHOTEL.BO) Income Statement Analysis – Financial Results
- James Bay Resources Limited (JMBRF) Income Statement Analysis – Financial Results
- Foran Mining Corporation (FOM.TO) Income Statement Analysis – Financial Results
- Innovative MedTech Inc. (IMTH) Income Statement Analysis – Financial Results
ThermoGenesis Holdings, Inc. (THMO)
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.45M | 10.48M | 9.29M | 9.74M | 13.05M | 9.67M | 12.03M | 14.53M | 11.93M | 16.04M | 15.99M | 17.96M | 19.02M | 23.40M | 23.09M | 19.80M | 21.95M | 16.75M | 12.05M | 10.18M | 11.65M | 10.19M | 9.55M | 5.79M | 4.21M | 5.10M | 4.50M | 6.60M | 4.10M | 3.30M | 2.70M | 2.00M | 1.80M | 1.80M | 1.10M | 1.20M | 500.00K | 100.00K |
| Cost of Revenue | 7.51M | 7.77M | 5.80M | 8.49M | 7.35M | 7.48M | 7.72M | 8.69M | 9.19M | 11.29M | 10.10M | 11.60M | 12.69M | 14.56M | 15.64M | 14.11M | 14.98M | 11.55M | 7.71M | 7.09M | 7.84M | 7.90M | 7.56M | 5.01M | 4.25M | 3.70M | 5.00M | 4.00M | 1.60M | 1.90M | 1.40M | 1.00M | 1.20M | 600.00K | 400.00K | 500.00K | 100.00K | 0.00 |
| Gross Profit | 1.93M | 2.71M | 3.49M | 1.26M | 5.70M | 2.19M | 4.31M | 5.84M | 2.74M | 4.75M | 5.89M | 6.37M | 6.33M | 8.84M | 7.45M | 5.69M | 6.97M | 5.20M | 4.34M | 3.09M | 3.80M | 2.29M | 1.99M | 780.00K | -35.00K | 1.40M | -500.00K | 2.60M | 2.50M | 1.40M | 1.30M | 1.00M | 600.00K | 1.20M | 700.00K | 700.00K | 400.00K | 100.00K |
| Gross Profit Ratio | 20.44% | 25.85% | 37.58% | 12.92% | 43.66% | 22.67% | 35.84% | 40.20% | 23.00% | 29.60% | 36.82% | 35.43% | 33.29% | 37.76% | 32.25% | 28.75% | 31.76% | 31.03% | 36.05% | 30.34% | 32.65% | 22.45% | 20.85% | 13.47% | -0.83% | 27.45% | -11.11% | 39.39% | 60.98% | 42.42% | 48.15% | 50.00% | 33.33% | 66.67% | 63.64% | 58.33% | 80.00% | 100.00% |
| Research & Development | 1.28M | 1.66M | 2.21M | 2.48M | 2.40M | 3.01M | 4.49M | 2.50M | 3.23M | 5.94M | 3.47M | 2.99M | 3.73M | 3.00M | 5.01M | 5.22M | 7.17M | 4.11M | 4.16M | 5.67M | 3.47M | 2.94M | 2.28M | 1.78M | 1.62M | 2.00M | 3.90M | 3.60M | 1.30M | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 5.73M | 6.38M | 8.29M | 7.92M | 10.87M | 8.23M | 10.70M | 8.49M | 5.65M | 5.22M | 5.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 1.95M | 1.66M | 1.36M | 1.69M | 1.53M | 2.15M | 2.97M | 2.97M | 2.96M | 2.76M | 3.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.22M | 7.24M | 8.52M | 7.68M | 8.03M | 9.65M | 9.01M | 12.40M | 10.38M | 13.67M | 11.46M | 8.60M | 7.98M | 8.67M | 7.69M | 9.25M | 10.17M | 9.63M | 7.16M | 5.84M | 5.17M | 5.01M | 4.84M | 3.89M | 4.20M | 4.80M | 4.60M | 3.50M | 1.60M | 1.10M | 1.80M | 1.30M | 1.90M | 1.30M | 1.10M | 1.00M | 1.30M | 600.00K |
| Other Expenses | 0.00 | -3.00K | 802.00K | -8.00K | -33.00K | -24.00K | 0.00 | 180.00K | -44.00K | 21.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.54M | 8.90M | 10.72M | 10.15M | 10.43M | 12.66M | 13.51M | 14.90M | 13.61M | 19.61M | 14.93M | 11.59M | 11.71M | 11.67M | 12.70M | 14.47M | 17.34M | 13.74M | 11.31M | 11.51M | 8.65M | 7.95M | 7.13M | 5.67M | 5.82M | 7.40M | 9.00M | 7.40M | 3.10M | 1.70M | 1.90M | 1.50M | 2.10M | 1.60M | 1.30M | 1.10M | 1.40M | 700.00K |
| Cost & Expenses | 18.33M | 16.68M | 16.53M | 18.64M | 17.78M | 20.14M | 21.22M | 23.58M | 22.79M | 30.90M | 25.03M | 23.19M | 24.40M | 26.24M | 28.34M | 28.58M | 32.31M | 25.29M | 19.02M | 18.60M | 16.49M | 15.85M | 14.68M | 10.68M | 10.07M | 11.10M | 14.00M | 11.40M | 4.70M | 3.60M | 3.30M | 2.50M | 3.30M | 2.20M | 1.70M | 1.60M | 1.50M | 700.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.19M | 1.77M | 828.00K | 216.00K | 90.00K | 0.00 | 110.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 5.62M | 6.10M | 7.91M | 4.48M | 2.70M | 0.00 | 20.52M | 7.99M | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K | 23.00K | 0.00 | 13.00K | 1.11M | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 100.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.15M | 926.00K | 633.00K | 754.00K | 806.00K | 670.00K | 644.00K | 830.00K | 1.17M | 1.35M | 993.00K | 538.00K | 604.00K | 466.00K | 492.00K | 474.00K | 543.00K | 549.00K | 118.00K | 367.00K | 302.00K | 266.00K | 434.00K | 485.00K | 677.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K | 200.00K | 200.00K | 300.00K | 200.00K | 100.00K | 100.00K | 100.00K |
| EBITDA | -7.74M | -5.27M | -6.60M | -8.16M | -4.73M | -42.30M | -8.55M | -8.42M | -9.70M | -13.49M | -8.05M | -4.69M | -4.78M | -2.37M | -4.76M | -8.30M | -9.82M | -7.99M | -6.85M | -8.06M | -4.54M | -5.40M | -4.70M | -4.41M | -5.18M | -5.40M | -9.00M | -4.50M | -400.00K | -100.00K | -500.00K | -300.00K | -1.30M | -100.00K | -400.00K | -300.00K | -900.00K | -500.00K |
| EBITDA Ratio | -81.95% | -50.27% | -62.36% | -83.75% | -30.47% | -101.51% | -71.11% | -55.41% | -81.66% | -84.07% | -50.33% | -38.13% | -25.10% | -10.12% | -20.63% | -41.94% | -44.76% | -47.71% | -56.87% | -79.15% | -39.00% | -52.99% | -49.23% | -76.07% | -122.94% | -105.88% | -200.00% | -68.18% | -9.76% | -12.12% | -18.52% | -15.00% | -72.22% | -5.56% | -36.36% | -33.33% | -200.00% | -600.00% |
| Operating Income | -8.61M | -6.19M | -7.23M | -8.90M | -4.73M | -43.55M | -9.20M | -9.37M | -10.87M | -14.86M | -9.04M | -3.07M | -5.38M | -2.84M | -5.25M | -8.78M | -10.37M | -8.54M | -6.97M | -8.42M | -4.84M | -5.66M | -5.14M | -4.89M | -5.85M | -6.00M | -9.50M | -4.80M | -600.00K | -300.00K | -600.00K | -500.00K | -1.50M | -400.00K | -600.00K | -400.00K | -1.00M | -600.00K |
| Operating Income Ratio | -91.16% | -59.08% | -77.80% | -91.29% | -36.28% | -450.22% | -76.47% | -64.50% | -91.08% | -92.63% | -56.55% | -17.06% | -28.28% | -12.12% | -22.76% | -44.34% | -47.24% | -50.99% | -57.85% | -82.76% | -41.59% | -55.60% | -53.78% | -84.44% | -139.02% | -117.65% | -211.11% | -72.73% | -14.63% | -9.09% | -22.22% | -25.00% | -83.33% | -22.22% | -54.55% | -33.33% | -200.00% | -600.00% |
| Total Other Income/Expenses | -10.31M | -5.62M | -4.65M | -7.92M | -5.37M | -2.13M | -1.00M | -20.53M | -7.72M | 7.00K | 6.00K | -21.00K | 393.00K | 268.00K | 61.00K | 228.00K | 1.19M | 1.77M | 0.00 | 202.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 600.00K | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K |
| Income Before Tax | -18.92M | -11.81M | -11.88M | -16.81M | -10.10M | -45.67M | -10.02M | -29.77M | -18.59M | -14.85M | -9.03M | -3.09M | -4.99M | -2.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | -900.00K | -500.00K |
| Income Before Tax Ratio | -200.31% | -112.68% | -127.82% | -172.53% | -77.40% | -472.19% | -83.29% | -204.94% | -155.82% | -92.58% | -56.51% | -17.18% | -26.21% | -10.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -25.00% | -180.00% | -500.00% |
| Income Tax Expense | 0.00 | 5.07M | 6.40M | 7.44M | 3.83M | -4.73M | -4.48M | -673.00K | 7.95M | 35.00K | -403.00K | -2.14M | 0.00 | 0.00 | -61.00K | -228.00K | -1.19M | -1.77M | -828.00K | -202.00K | -67.00K | -61.00K | -97.00K | 1.84M | -36.00K | 100.00K | 100.00K | 0.00 | 0.00 | -200.00K | 0.00 | -200.00K | 0.00 | 300.00K | 200.00K | 100.00K | 100.00K | 200.00K |
| Net Income | -17.98M | -11.27M | -11.38M | -16.35M | -9.50M | -39.72M | -4.57M | -29.10M | -18.59M | -14.85M | -8.63M | -3.09M | -4.99M | -2.57M | -5.19M | -8.55M | -9.18M | -6.78M | -6.14M | -8.22M | -4.78M | -5.60M | -5.04M | -6.73M | -5.82M | -6.10M | -9.60M | -4.80M | -600.00K | -100.00K | 0.00 | -300.00K | -1.50M | -700.00K | -800.00K | -500.00K | -1.10M | -800.00K |
| Net Income Ratio | -190.31% | -107.51% | -122.43% | -167.81% | -72.79% | -410.63% | -37.97% | -200.31% | -155.82% | -92.58% | -53.99% | -17.18% | -26.21% | -10.97% | -22.49% | -43.18% | -41.83% | -40.45% | -50.98% | -80.77% | -41.02% | -55.00% | -52.76% | -116.25% | -138.16% | -119.61% | -213.33% | -72.73% | -14.63% | -3.03% | 0.00% | -15.00% | -83.33% | -38.89% | -72.73% | -41.67% | -220.00% | -800.00% |
| EPS | -7.59 | -20.45 | -43.41 | -117.20 | -151.09 | -971.34 | -203.28 | -1.32K | -2.78K | -3.31K | -3.21K | -1.68K | -2.74K | -1.56K | -3.33K | -5.49K | -5.93K | -4.42K | -4.46K | -6.52K | -4.12K | -5.51K | -5.15K | -7.63K | -8.44K | -10.66K | -18.29K | -10.91K | -1.70K | -283.29 | 0.00 | -1.17K | -6.07K | -3.20K | -4.65K | -3.73K | -8.27K | -6.67K |
| EPS Diluted | -7.59 | -20.45 | -43.41 | -117.20 | -151.09 | -971.34 | -203.28 | -1.32K | -2.78K | -3.31K | -3.21K | -1.68K | -2.74K | -1.56K | -3.33K | -5.49K | -5.93K | -4.42K | -4.46K | -6.52K | -4.12K | -5.51K | -5.15K | -7.63K | -8.44K | -10.66K | -18.29K | -10.91K | -1.70K | -283.29 | 0.00 | -1.17K | -6.07K | -3.20K | -4.65K | -3.73K | -8.27K | -6.67K |
| Weighted Avg Shares Out | 2.37M | 550.99K | 262.13K | 139.51K | 62.86K | 40.89K | 22.46K | 22.04K | 6.69K | 4.48K | 2.69K | 1.84K | 1.82K | 1.65K | 1.56K | 1.56K | 1.55K | 1.53K | 1.38K | 1.26K | 1.16K | 1.02K | 978.00 | 883.00 | 689.00 | 572.00 | 525.00 | 440.00 | 353.00 | 353.00 | 282.00 | 257.00 | 247.00 | 219.00 | 172.00 | 134.00 | 133.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 2.37M | 550.99K | 262.13K | 139.51K | 62.86K | 40.89K | 22.46K | 22.04K | 6.69K | 4.48K | 2.69K | 1.84K | 1.82K | 1.65K | 1.56K | 1.56K | 1.55K | 1.53K | 1.38K | 1.26K | 1.16K | 1.02K | 978.00 | 883.00 | 689.00 | 572.00 | 525.00 | 440.00 | 353.00 | 353.00 | 282.00 | 257.00 | 247.00 | 219.00 | 172.00 | 134.00 | 133.00 | 120.00 |
ThermoGenesis Holdings, Inc. (THMO) Q1 2023 Earnings Call Transcript
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee...
Why Is ThermoGenesis (THMO) Stock Up 54% Today?
ThermoGenesis (NASDAQ: THMO ) stock is rocketing higher on Thursday after the company announced new cGMP Suites. These cGMP Suites are for early-stage life science and cell gene therapy companies.
Why ThermoGenesis Stock Is Soaring Wednesday
ThermoGenesis said it plans to rent out its current Good Manufacturing Practices suites in the second and third quarters. The company was nearly delisted from the Nasdaq last year.
THMO Stock Alert: Why ThermoGenesis Is Up 95% Today
What's causing ThermoGenesis Holdings (NASDAQ: THMO ) stock traders to suddenly go on a buying binge? Evidently, the share-price rally is prompted by ThermoGenesis's announcement that it's launching a new facility in the Sacramento metro area of California.
ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q3 2022 Results - Earnings Call Transcript
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean...
ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif. , Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release...
ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q2 2022 Results - Earnings Call Transcript
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q2 2022 Results Conference Call August 11, 2022 3:00 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean...
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif. , Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field,...
Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins
Penny stocks to watch right now The post Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports